Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Some of today’s most popular products promise better immune, adaptogenic, anti-inflammatory, gut, skin or joint health—or combinations of two or more of the above.
The company called the state’s regulation of pharmacy benefit managers “shortsighted,” as it would force the closure of Accredo, a specialty drug dispensary that supplies drugs it says aren’t available anywhere else in the state.
The agency had been suing the three largest pharmacy benefit managers over their alleged control of insulin prices. It reached agreements with CVS’ Caremark and Cigna’s Express Scripts earlier this year.
The collaboration between the chipmaker and Abridge, a developer of generative AI for healthcare, will involve data-sharing to improve Nvidia’s general-purpose models, which in turn will be used to make Abridge’s clinical offerings more efficient.
The Kentucky-based insurance giant had owned a 40% stake in the hospice company, stemming from its 2021 acquisition of Kindred Healthcare. Humana said a “consortium of investors" is making the buy, but few details were revealed.
Many hospitals that use Epic were unable to access services, forcing them to operate on pen-and-paper and cancel non-emergency care delivery. The disruption was caused by an error with security vendor CrowdStrike.
Citing two sources familiar with the matter, journalists at CBS News said the health system is suspected of violating the Foreign Corrupt Practices Act. No charges have been filed.
When it comes to adopting healthcare AI, large, well-off hospitals are likely to frequently homer while smaller, struggling institutions go down looking. (Baseball analogy in honor of tonight’s Midsummer Classic.)
Morphic's new treatment for inflammatory bowel disease is in Phase II clinical trials and shows promise in improving patient outcomes. Eli Lilly will purchase the company for $57 per share in cash.